Pharmacokinetics and bioavailability of carprofen in sheep

Basit Öğe Kaydı
dc.authoridCoskun, Devran/0000-0003-1151-1861
dc.authoridElmas, Prof. Dr., Muammer/0000-0001-9059-7151
dc.authoridCorum, Orhan/0000-0003-3168-2510
dc.authoridUney, Kamil/0000-0002-8674-4873
dc.contributor.authorCoskun, Devran
dc.contributor.authorCorum, Orhan
dc.contributor.authorDurna Corum, Duygu
dc.contributor.authorUney, Kamil
dc.contributor.authorElmas, Muammer
dc.date.accessioned2024-12-24T19:29:35Z
dc.date.available2024-12-24T19:29:35Z
dc.date.issued2022
dc.departmentSiirt Üniversitesi
dc.description.abstractThe aim of this study was to determine the pharmacokinetics and bioavailability of carprofen in sheep following single intravenous (IV), intramuscular (IM), subcutaneous (SC), and oral (PO) administrations of a parenteral formulation at a dose of 4 mg/kg. A total of eight sheep were used for the investigation. The study comprised four periods, according to a crossover design with a 21-day washout period between treatments. Plasma concentrations of carprofen were measured using HPLC-UV. Pharmacokinetic parameters were estimated by non-compartmental model analysis. Following IV administration, t(1/2 lambda z), Cl-T, and V-dss were 43.36 h, 1.98 ml/h/kg, and 121.36 ml/kg, respectively. The C-max(obs) was 26.57 mg/ml for the IM, 23.76 mg/ml for the SC, and 15.90 mg/ml for the PO. The bioavailability following IM, SC, and PO administrations was 75.47%, 82.00%, and 62.51%, respectively. Plasma creatine kinase activity increased significantly at 3, 6, and 12 h following IM administration of carprofen. Despite differences in plasma concentrations and bioavailability among administration routes, carprofen at 4 mg/kg dose may provide the plasma concentration (>1.5 mu g/ml) needed for analgesic effect during 144 h in all routes. However, because of the slow absorption rate after SC and PO routes, the IV route may be preferred primarily for the rapid onset in the analgesic and anti-inflammatory effect of carprofen in sheep. Despite the favorable kinetics, the muscle damage caused by IM injection limits use of carprofen via IM route.
dc.description.sponsorshipCoordination of Scientific Research Projects, University of Siirt, Turkiye [2020-SIUVET-039]
dc.description.sponsorshipThis study was supported by The Coordination of Scientific Research Projects, University of Siirt, Turkiye (Project No. 2020-SIUVET-039).
dc.identifier.doi10.1111/jvp.13085
dc.identifier.endpage549
dc.identifier.issn0140-7783
dc.identifier.issn1365-2885
dc.identifier.issue6
dc.identifier.pmid35768899
dc.identifier.scopus2-s2.0-85133070102
dc.identifier.scopusqualityQ1
dc.identifier.startpage543
dc.identifier.urihttps://doi.org/10.1111/jvp.13085
dc.identifier.urihttps://hdl.handle.net/20.500.12604/7149
dc.identifier.volume45
dc.identifier.wosWOS:000818689800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal of Veterinary Pharmacology and Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_20241222
dc.subjectbioavailability
dc.subjectcarprofen
dc.subjectpharmacokinetics
dc.subjectsheep
dc.titlePharmacokinetics and bioavailability of carprofen in sheep
dc.typeArticle

Dosyalar

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu